Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
At Hospital/Institution:  Presbyterian - St. Luke's Medical Center, Presbyterian - St. Luke's Medical Center
Keywords/Phrases:  gastrointestinal cancer
Results 1-25 of 4597 for your search:
Start Over
Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 201404101, NCI-2013-00650, NCT01790035
Ropidoxuridine in Treating Patients with Advanced Gastrointestinal Cancer Undergoing Radiation Therapy
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BrUOG 265, NCI-2015-00258, 9882, NCT02381561
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BBI608-246, NCI-2015-00892, NCT02024607
Ganetespib and Ziv-Aflibercept in Treating Patients with Refractory or Metastatic Gastrointestinal Cancer, Non-small Cell Lung Cancer, Urothelial Cancer, or Sarcoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 and over
Trial IDs: 14-C-0150, NCI-2014-00626, 09-25-0099, 141525, P141525, 9605, NCT02192541
Continuous Activity Monitoring during Fractionated Radiotherapy in Patients with Head and Neck, Lung, or Gastrointestinal Cancer
Phase: No phase specified
Type: Natural history/Epidemiology
Age: 18 and over
Trial IDs: 2015-4873, NCI-2015-02292, 007067, NCT02649569
Genetic Analysis-Guided Dosing of FOLFIRABAX in Treating Patients with Advanced Gastrointestinal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB14-0595, NCI-2014-02407, NCT02333188
Blood and Tumor Tissue Samples Collected from Patients with Gastrointestinal Cancer
Phase: No phase specified
Type: Biomarker/Laboratory analysis
Age: 18 and over
Trial IDs: 11-C-0112, NCI-2015-01225, 311713, P10747, NCT01313442
Mutation-Targeted Therapy with Sunitinib Malate or Everolimus in Treating Patients with Advanced Neuroendocrine Tumors of the Gastrointestinal Tract or Pancreas
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15-C-0040, NCI-2015-00091, 150040, 339636, P141605, NCT02315625
Alisertib and Combination Chemotherapy in Treating Patients with Gastrointestinal Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: VICC GI1536, NCI-2014-02475, 9824, NCT02319018
Long-Term Follow up for Patients Previously Enrolled in National Cancer Institute Surgery Branch Studies
Phase: No phase specified
Type: Natural history/Epidemiology
Age: 16 and over
Trial IDs: 09-C-0161, NCI-2015-01184, 090161, 304795, 344944, P09518, NCT00923026
Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: OX4219s, NCI-2015-00120, NCT02279602
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology
Age: 18 and over
Trial IDs: CGI-061, NCI-2013-01950, NCT02092714
Ribociclib in Treating Patients with Advanced Neuroendocrine Tumors of Foregut Origin
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0371, NCI-2015-01017, NCT02420691
Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SNX5422-CLN-009, NCI-2014-02577, NCT02063958
A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care
Age: 18 and over
Trial IDs: AAA-III-01, NCI-2012-02037, 2011-005049-11, NCT01578239
Pazopanib Hydrochloride in Treating Patients with Progressive Carcinoid Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A021202, NCI-2013-00831, ALLIANCE A021202, CALGB-A021202, NCT01841736
68Ga-DOTA-JR11and 177Lu-DOTA-JR11 PET/CT in Diagnosing and Treating Patients with Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 15-161, NCI-2015-02110, NCT02609737
Electronic Monitoring Device of Patient-Reported Outcomes and Function in Improving Patient-Centered Care in Patients with Gastrointestinal Cancer Undergoing Surgery
Phase: No phase specified
Type: Supportive care
Age: 21 and over
Trial IDs: 15051, NCI-2015-01061, 117195, 119277, 120511, 15051/117195, NCT02511821
Regorafenib in Treating Patients with Advanced or Metastatic Neuroendocrine Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 0S-14-3, NCI-2014-01996, HS-14-00583, NCT02259725
Aerobic Exercise in Improving Cardiopulmonary Fitness and Tumor Neoplastic Phenotype in Patients with Gastrointestinal Cancer Undergoing Radiation Therapy and Surgery
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Supportive care
Age: 18 and over
Trial IDs: Pro00055718, NCI-2015-02146, NCT02235441
A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BBI401-101, NCI-2015-02290, NCT02432326
Domperidone in Treating Patients with Gastrointestinal Disorders
Phase: Phase III
Type: Treatment
Age: 16 and over
Trial IDs: 2012-0261, NCI-2012-02093, NCT01696734
Surgery or Non-surgical Management in Treating Patients with Intra-abdominal Cancer and Bowel Obstruction
Phase: Phase III
Type: Supportive care
Age: 18 and over
Trial IDs: S1316, NCI-2014-01497, SWOG/S1316, NCT02270450
Pasireotide in Reducing Gastrointestinal Toxicity from Chemotherapy and Radiation Therapy in Patients Undergoing a Donor Stem Cell Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: Pro00051736, NCI-2014-02316, NCT02215070
Start Over